8:15–10:15

MORNING SESSION—ASSESSING THE CURRENT STATE OF BIOMARKERS TO PREDICT DRUG-INDUCED TOXICITY.

• What is the current state of the art for screening technologies to find off-target effects early in development—what have we been able to accomplish, and what remains to be done?

• What are the obstacles impeding progress?

• How can these efforts be accelerated through public and private means?

Moderator:

MIKHAIL GISHIZKY (Forum Member)

Entelos

8:15–8:30

Overview

ALASTAIR WOOD

Symphony Capital, LLC

8:30–8:45

Cardiac Toxicity

NORMAN STOCKBRIDGE

U.S. Food and Drug Administration

DANIEL BLOOMFIELD

Merck Research Laboratories

8:45–9:00

Hepatotoxicity

PAUL WATKINS

University of North Carolina at Chapel Hill

9:00–9:15

Nephrotoxicity

FRANK SISTARE

Merck Research Laboratories

9:15–10:10

Panel Discussion

10:10–10:15

Charge to the Breakout Groups

ROBERT CALIFF (Forum Member)

Duke University Medical Center